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Abstract
Background: The aim of this study is to compare the circulating placental growth 
factor (PlGF) concentration in women with and without endometrioma to verify the 
performance of this marker to diagnose the disease.  
Materials and Methods: In this case-control study, thirteen women with histological diag-
nosis of ovarian endometriosis were compared with women without endometriosis disease. 
PlGF plasma levels of endometriotic patients and controls were investigated using a fluores-
cence immunoassay technique.    
Results: PlGF showed a direct correlation with body mass index (BMI) only in the 
control group (P=0.013). After adjustment for BMI values, PlGF median value in 
endometriosis group (14.7 pg/mL) resulted higher than in control group (13.8 pg/
mL, P=0.004).      
Conclusion: PlGF is a promising peripheral blood marker that can discriminate between 
patients with and without ovarian endometriosis.   
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Introduction 
Endometriosis is a estrogen-dependent chronic 
disorder often resulting in morbidity, pelvic pain 
and infertility (1). Although endometriosis typical-
ly appears benign on histological examination, it 
is characterized by a malignant tumour-like nature 
in that it grows, infiltrates and adheres to the sur-
rounding tissues. The gold standard for diagnosis 
is laparoscopic surgery with histologic confirma-
tion. However, every surgical procedure has po-
tential risks for patients (2). Ultrasound should be 
the first-line imaging modality for the evaluation 
of patients with suspected endometriosis. Its ac-
curacy has greatly improved over recent years, but 
its performance is heavily operator-dependent (3). 
Detection of simple and non-invasive diagnostic 
test is one of the priorities in endometriosis re-
search.
Most of the proposed non-invasive diagnosis 
methods are based on the identification of bio-
markers believed to be involved in the pathophysi-
ology of the disease and differentially expressed 
in the peripheral blood of patients as compared to 
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health subjects. The increasing interest in angioge-
netic factors as putative peripheral blood markers 
for endometriosis is not surprising, since several 
lines of evidence suggest that the angiogenetic 
factors are involved in the establishment of neo-
vascularization requirement for development and 
maintenance of endometriosic lesion (4-8).
Vascular endothelial growth factor (VEGF) is 
the most widely studied angiogenetic factor. Al-
though several authors have evaluated serum or 
peripheral blood levels of VEGF in endometriosis 
patients, contradictory results have been reported 
and the validity of using VEGF in endometriosis 
diagnosis has not been definitely attested (9-17).
Placental growth factor (PlGF) is a member of 
the proangiogenic vascular endothelial growth 
factor family (18, 19). PLGF presented some sim-
ilarities to the structure of VEGF-A with a 42% 
amino acid sequence identity. Nevertheless, they 
have significant functional differences. PlGF was 
originally identified in the placenta, where it has 
been proposed to control trophoblast growth, dif-
ferentiation and invasion (20-22). Its biological ef-
fect is mediated by VEGF receptor 1 (VEGFR-1), 
a tyrosine kinase receptor expressed on the surface 
of several cell types including endothelial cells, 
macrophages, bone marrow precursors and can-
cer cells (23). PlGF shows a high disease-specific 
activity and its contribution to the angiogenetic 
switch in pregnancy, wound healing, ischemic 
conditions and tumor growth has been well docu-
mented (24-30). In cancer, PlGF may also facilitate 
metastasis by increasing the motility and invasion 
of malignant cells, and it has been demonstrated 
that the levels of PlGF in plasma and serum cor-
relate with tumor stage and poor survival in vari-
ous tumors (31-37). Despite the above-mentioned 
angiogenetic and prometastatic activities, the role 
of PlGF as candidate biomarker in diagnosis of 
endometriosis has been poorly investigated. Suzu-
mori et al. (38) have indicated increased levels of 
placental growth factor in the peritoneal fluid of 
women with endometriosis compared with women 
with cystadenomas, suggesting that the production 
of PlGF may contribute to the pathogenesis of en-
dometriosis by promoting neovascularization.
We aim to analyze and to compare the preoperative 
PlGF concentration in the peripheral blood of women 
with and without ovarian endometriosis in order to 




In the present case-control study, we enrolled a to-
tal of 26 women in our center of Pelvic Endoscopy 
and Minimally Invasive Gynaecologic Surgery, S. 
Orsola-Malpighi University of Bologna, Bologna, 
Italy, from October 2012 through September 2013. 
Ethics Committee approval of S. Orsola-Malpighi 
Hospital was obtained before starting the data collec-
tion. The approval code is PLGF 167/2012/O/Tess. 
All study subjects provided a written informed con-
sent for the use of biological specimens for research 
purposes. Thirteen patients (group A) with a preoper-
ative ultrasound diagnosis of ovarian endometriosis 
(defined as the presence of a unilocular cyst with a 
regular wall and homogeneous low-level echogenic-
ity of the cyst’s content), subsequently confirmed by 
histological analysis (Fig.1), were included in the 
study. For each case, a consecutive control of same 
age, parity and BMI without endometriosis disease 
was recruited; therefore, a 1:1 match was generated. 
Patients of the control group (group B) were operated 
for leiomyoma pathology. Again, we excluded primi/
pluriparae women with history of pre-eclampsia and/
or intrauterine fetal growth restriction (IUGR). All 
patients were submitted on peripheral blood collec-
tion during the proliferative phase of the menstrual 
cycle and they were not on hormonal treatment since 
at least 3 months (Table 1).
Blood samples/measurement of placental growth 
factor concentration 
A peripheral blood sample (10 ml) from each 
woman enrolled in our study was collected in 
sterile tubes containing ethylenediaminetetraacet-
ic acid (EDTA) and treated for PlGF evaluation 
within 2 hours of being drawn. Blood samples 
were centrifuged at 1500 g for 10 minutes at 
4˚C; the obtained plasma samples were stored 
at –20˚C until the measurement of PlGF plasma 
levels. PlGF quantification was performed by 
the Alere PlGF Test (Fig.2) using Triage® Me-
terPro instrument (Alere Srl, Italy), according 
to the manufacturer’s instructions. The test is 
based on a fluorescence immunoassay technique 
and provides a PlGF measurable range of 12 to 
3,000 pg/mL.
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Table 1: Demographic and clinical characteristics of the data set
P value*Endometriosis Cases (n=13)Controls (n=13)Variable








-7.7 (28.5 mm)-Right  side  % (median mm)
-53.8 (36.0 mm)-Left side % (median mm)
-38.5-Bilaterality (%)
0.57222.3 (19.6-31.1)22.1 (18.8-29.7)Median BMI (minimum-maximum)
0.00414.7 (14.5-21.0)13.8 (13.7-18.6)Median PlGF (minimum-maximum) (pg/mL)
*; Mann-Whitney U test or Fisher exact test, BMI; Body mass index and PlGF; Placental growth factor.
Fig.1: Histology of an ovarian endometriosis cyst wall showing endometrial tissue in the muscular layer with granulation tissue. A. Hae-
matoxylin and eosin (H&E) staining method (×4 magnification) and B. The cyst wall is lined by cylindrical endometrial-type epithelium. 
(H&E) staining method (×10 magnification).
Fig.2: Placental growth factor (PlGF) measurement instrument.
A B
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Statistical analysis
Descriptive statistics was performed by means of 
routine analysis. Adjustment for possible confound-
ing variables was performed by means of a general 
linear model (GLM) having PlGF as dependent vari-
able plotted versus any possible correlated variable. 
Mann-Whitney U test and Chi square or Fisher exact 
test were used to compare the two generated groups of 
patients. Finally a non -parametric Receiver Operator 
Characteristics (ROC) curve was generated in order 
to calculate the sensitivity of adjusted PlGF values 
for endometriosis at fixed rate of false positive. A two 
tails P<0.05 was considered statistically significant.
Results
PlGF showed a direct correlation with body mass 
index (BMI), but only in the control group (P=0.013). 
For endometriosis group, in fact, PlGF lost its signifi-
cant correlation with BMI (P=0.178) as showed in 
figure 3. After adjustment for BMI values and using 
the parameters of regression model quoted for the 
controls, the PlGF in endometriosis group resulted in 
a slight higher median value when compared to that of 
the control group (P=0.004) as reported in table 1. A 
non-significant direct correlation was found between 
PlGF and parity and it was excluded from the final 
model. There was no difference for all the other vari-
ables considered in the data set as reported in table 1.
ROC curve yielded a sensitivity of PlGF for endo-
metriosis of 80% at a fixed false positive rate (FPR) of 
20% about, with an area under the curve (AUC)=0.834 
(95%CI=0.649-1.020) and a P=0.004 (Fig.4).
Fig.3: Log-Linear regression of BMI vs. PlGF in controls and cases. As shown significant association has been found only for controls (P=0.013). For 
endometriosis cases, PlGF lost its significant correlation with BMI (P=0.178). BMI; Body mass index and PlGF; Placental growth factor.
Fig.4: Receiver operator characteristics (ROC) curve for detection of endometriosis using placental growth factor (PlGF) as explorative 
variable. The sensitivity of PlGF for endometriosis was 80% at a fixed false positive rate (FPR) of 20% about, with an area under the curve 
(AUC)=0.834 (95%CI=0.649-1.020) and  P=0.004. 
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Discussion
To date, the gold standard for diagnosis of endo-
metriosis is laparoscopic surgery (2). This limita-
tion, together with the long delay between the on-
set of symptoms and diagnosis of endometriosis, 
is the main reasons for the urgent require of a non-
invasive diagnosis method.
Ultrasound is also accurate, but only if performed 
by an expert operator (3). Detection of simple and 
non-invasive diagnostic test is one of the priorities 
in endometriosis research.
The identification of peripheral blood markers, 
capable of diagnosing or excluding endometriosis, 
could avoid the need for an invasive procedure 
(39, 40) or at least allow symptomatic women to 
be screened. Nevertheless, a biomarker with high 
sensitivity, specificity and clinical relevance use-
ful for non-invasive diagnosis of endometriosis, is 
still unidentified.
From the pathophysiological point of view, it has 
been demonstrated that the ectopic implants of en-
dometrial cells are rich in angiogenetic growth fac-
tors and it is well known that the establishment of 
a new blood supply is crucial for the development 
of endometriotic lesions.  Taking into account the 
importance of angiogenesis in the pathogenesis of 
the disease (7), in this study, we assessed the role 
of PlGF, a member of the proangiogenic VEGF 
family, as putative circulating biomarkers of en-
dometriosis.
We demonstrated that PlGF correlates with BMI 
in controls as a possible biological epiphenomenon 
of some tissue release. Whereas in endometriosis 
patients, this direct association is lost probably for 
a secondary confounding effect due to the pres-
ence of the disease. After adjustment for BMI, in 
fact, the PlGF resulted higher in ovarian endome-
triosis patients. Again, even if the PlGF increase in 
endometrioma is quite small, it is statistically sig-
nificant by means of non-parametric analysis. Sev-
eral authors have previously reported a direct as-
sociation between BMI and both VEGF and PlGF 
plasma levels (41-44). In endometriosis patients, 
both actual PlGF values and correlation with BMI 
described in control subjects seems altered. Re-
gardless of the mechanistic link between BMI and 
increased circulating angiogenetic factors, which 
has not been clarified yet, the impairment of the 
relationship between BMI and circulating PlGF 
suggests the involvement of this proangiogenic 
factor in endometriosis. It may be considered an 
indicator of the disease.
Despite the small differences in PlGF values, a 
ROC curve yielded a significant AUC with a sensi-
tivity of 80% about at FPR of 20%. The associated 
PlGF cut-off was 15 pg/mL. For the linear regres-
sion, given a sample size of 13 subjects, a power 
of 83% at a 5% of type I error is reached for a 
R2=0.6. Given the R2 found in this study (0.579 
and 0.292 for controls and cases, respectively), the 
sample size required to reach a proper power was 
17 and 87. Our samples reached instead a power 
of 64 and 17 at a 5% of type I error. For the ROC 
curve, instead, a sample size of 26 cases (13+13) 
and an AUC of 0.834 yielded a power of 95% at a 
type I error of 5%. Even if this is a small series of 
data, the results seem encouraging for a possible 
use of PlGF in ovarian endometriosis evaluation in 
prospective studies. An increasing number of re-
ports has documented that PlGF activity does not 
affect quiescent vessels in healthy tissues, but it 
has a role in vessel stabilization under pathological 
conditions (24-27). This disease-restricted activity 
of PlGF is an attractive property that could help 
to discriminate between pathological and health 
conditions. However, the involvement of PlGF in 
many other angiogenetic diseases raises the ques-
tion whether PlGF could be specific enough to be 
proposed as a marker of endometriosis and further 
explorations are needed to clarify this issue.
A noteworthy feature of our study is that it em-
ploys a highly reproducible and easily-applied 
technique of PlGF quantification. This method is 
readily amenable, employs no toxic reagents and is 
very fast. These features make the procedure feasi-
ble in terms of clinical management and/or large-
scale screening.
Conclusion
Our study identifies PlGF level as a promising 
biological indicator that could help to discriminate 
between patients with ovarian endometriosis and 
healthy subjects. Further investigations are needed 
to explore PlGF specificity degree and to confirm 
its prognostic/diagnostic value in clinical practice. 
Nevertheless, our results support the possibility of 
finding an easily detectable peripheral blood marker 
that alone or within a panel of others biomarkers 
could improve the diagnosis of endometriosis in 
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